CMND-100 Trial Begins Testing in Alcohol Use Disorder
Patients are now participating in clinical testing of a potential new treatment for alcohol use disorder.
Updated on Oct. 27, 2026 in Substance Abuse
Live Poll
Do you trust pharmaceutical companies to properly prioritize patient safety during early-stage clinical drug trials?
Clearmind Medicine has finished recruiting the first group of patients for its Phase I/IIa clinical trial of CMND-100. This study evaluates the safety and potential efficacy of the treatment in individuals diagnosed with moderate-to-severe Alcohol Use Disorder.
Why it matters
The transition from healthy volunteers to patients with Alcohol Use Disorder marks a critical stage in evaluating whether CMND-100 can safely address this complex condition. This trial aims to generate the foundational data needed to determine if the compound has clinical potential.
This Phase I/IIa trial involves sequential single-dose ascending cohorts of 80 mg and 160 mg, each consisting of six patients with moderate-to-severe Alcohol Use Disorder. The clinical findings are currently preliminary as the company continues its evaluation of safety and efficacy signals.
The players
Clearmind Medicine
A pharmaceutical company headquartered in Vancouver that develops compounds for Alcohol Use Disorder and other mental health conditions.
Johns Hopkins University School of Medicine
A research institution evaluating the clinical safety and pharmacokinetics of the investigational compound.
Yale School of Medicine
An academic medical center serving as a site for assessing the trial drug in patients with addiction.
Tel Aviv Sourasky Medical Center
A major Israeli hospital participating in the international clinical investigation of the study drug.
Hadassah Medical Center
A clinical research site in Israel conducting patient evaluations for the CMND-100 trial.
The details
The trial utilizes a dose-escalation design to monitor the safety, tolerability, and pharmacokinetics of CMND-100. Researchers are specifically observing participants for physiological signals and potential reductions in alcohol cravings. By testing ascending doses, the team aims to establish how the drug interacts with the body before moving forward with clinical development.
Timeline
October 27, 2026: Clearmind Medicine announced the completion of patient recruitment for the first cohort.
Health Landscape
The study sits within the broader, ongoing effort to identify new therapeutic pathways for managing Alcohol Use Disorder. It follows a historical arc of clinical development where researchers test novel compounds against standard care to address persistent gaps in addiction treatment.
This development is a preliminary research milestone and does not impact current treatment plans or medication availability for patients. Individuals seeking support for alcohol use should consult their physician to discuss established evidence-based therapies and local resources.
The takeaway
Advancements in clinical trials for addiction treatments serve as important indicators of future options for care. Patients should focus on maintaining open conversations with their healthcare team about existing, proven treatments for managing alcohol use.
Further reading
Learn more about the latest research and standard approaches in Substance Abuse.
More information
For more information on the company's research pipeline, visit the company official website.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you trust pharmaceutical companies to properly prioritize patient safety during early-stage clinical drug trials?
